Baker Bros. Advisors
Latest statistics and disclosures from Baker Bros. Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are INCY, ONC, INSM, MDGL, ACAD, and represent 50.51% of Baker Bros. Advisors's stock portfolio.
- Added to shares of these 10 stocks: PRAX (+$202M), INSM (+$136M), GRAL (+$100M), MIRM (+$41M), CRNX (+$26M), ELVN (+$25M), EVMN (+$20M), IONS (+$19M), Aktis Oncology (+$18M), Generate Biomedicines Ord (+$18M).
- Started 7 new stock positions in Aktis Oncology, Eikon Therapeutics, Generate Biomedicines Ord, EVMN, CMPS, VSTM, MIRM.
- Reduced shares in these 10 stocks: RARE (-$64M), IMCR (-$48M), TERN (-$38M), BNTX (-$22M), , VTYX (-$21M), ROIV (-$19M), NUVL (-$15M), IMTX (-$12M), ARWR (-$12M).
- Sold out of its positions in ACRV, BCRX, FDMT, KALA, NUVL, TERN, RARE, VTYX, VIR.
- Baker Bros. Advisors was a net buyer of stock by $397M.
- Baker Bros. Advisors has $17B in assets under management (AUM), dropping by 1.97%.
- Central Index Key (CIK): 0001263508
Tip: Access up to 7 years of quarterly data
Positions held by Baker Bros. Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Baker Bros. Advisors
Baker Bros. Advisors holds 84 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Incyte Corporation (INCY) | 16.6 | $2.9B | 31M | 94.12 |
|
|
| BeOne Medicines Sponsored Ads (ONC) | 15.0 | $2.6B | 8.8M | 296.97 |
|
|
| Insmed Incorporated Com Par $.01 (INSM) | 7.0 | $1.2B | +12% | 7.4M | 163.52 |
|
| Madrigal Pharmaceuticals (MDGL) | 6.4 | $1.1B | 2.1M | 523.47 |
|
|
| ACADIA Pharmaceuticals (ACAD) | 5.5 | $955M | 43M | 22.26 |
|
|
| Revolution Medicines (RVMD) | 5.3 | $929M | 9.6M | 97.25 |
|
|
| Celcuity (CELC) | 5.2 | $904M | 7.9M | 114.14 |
|
|
| Kodiak Sciences (KOD) | 4.4 | $759M | 20M | 38.12 |
|
|
| Kymera Therapeutics (KYMR) | 4.1 | $721M | 8.7M | 83.29 |
|
|
| Summit Therapeutics (SMMT) | 4.0 | $690M | 36M | 18.96 |
|
|
| Praxis Precision Medicines I (PRAX) | 3.2 | $565M | +55% | 1.8M | 322.19 |
|
| Rhythm Pharmaceuticals (RYTM) | 2.8 | $487M | 5.6M | 86.97 |
|
|
| Alkermes SHS (ALKS) | 2.0 | $354M | 10M | 35.36 |
|
|
| Grail (GRAL) | 1.2 | $208M | +93% | 4.0M | 51.68 |
|
| Edgewise Therapeutics (EWTX) | 1.2 | $207M | 6.6M | 31.50 |
|
|
| Ionis Pharmaceuticals (IONS) | 0.9 | $154M | +14% | 2.0M | 75.09 |
|
| Kiniksa Pharmaceuticals International Ord Shs Cl A (KNSA) | 0.8 | $136M | 2.8M | 48.15 |
|
|
| Immunovant (IMVT) | 0.8 | $136M | 5.5M | 24.84 |
|
|
| Roivant Sciences SHS (ROIV) | 0.8 | $135M | -12% | 4.9M | 27.70 |
|
| Ideaya Biosciences (IDYA) | 0.8 | $132M | +9% | 3.9M | 33.32 |
|
| Arrowhead Pharmaceuticals (ARWR) | 0.7 | $125M | -8% | 2.0M | 62.70 |
|
| Stoke Therapeutics (STOK) | 0.6 | $109M | 3.3M | 32.56 |
|
|
| Immatics SHS (IMTX) | 0.6 | $107M | -9% | 11M | 9.84 |
|
| Abcellera Biologics (ABCL) | 0.6 | $106M | +9% | 30M | 3.49 |
|
| Abivax Sponsored Ads (ABVX) | 0.6 | $98M | 876k | 111.35 |
|
|
| Crinetics Pharmaceuticals In (CRNX) | 0.5 | $85M | +42% | 2.4M | 36.32 |
|
| Replimune Group (REPL) | 0.5 | $85M | 11M | 7.65 |
|
|
| Celcuity Note 2.75% 8/1/2031 | 0.4 | $75M | 31M | 2.43 |
|
|
| Nurix Therapeutics (NRIX) | 0.4 | $72M | 4.7M | 15.50 |
|
|
| Denali Therapeutics (DNLI) | 0.4 | $72M | 3.7M | 19.20 |
|
|
| Dianthus Therapeutics (DNTH) | 0.4 | $72M | +7% | 852k | 83.92 |
|
| Monte Rosa Therapeutics (GLUE) | 0.4 | $72M | 4.3M | 16.45 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.4 | $69M | 1.4M | 48.20 |
|
|
| Entrada Therapeutics (TRDA) | 0.4 | $64M | 5.1M | 12.62 |
|
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 0.3 | $51M | 11M | 4.64 |
|
|
| Aeglea Biotherapeutics (SYRE) | 0.3 | $50M | 1.0M | 50.44 |
|
|
| Rapport Therapeutics (RAPP) | 0.3 | $48M | 1.5M | 31.29 |
|
|
| Alumis (ALMS) | 0.3 | $44M | +28% | 2.0M | 22.03 |
|
| Mirum Pharmaceuticals (MIRM) | 0.2 | $41M | NEW | 446k | 92.38 |
|
| Miragen Therapeutics (VRDN) | 0.2 | $39M | 2.0M | 19.56 |
|
|
| Enliven Therapeutics (ELVN) | 0.2 | $36M | +233% | 905k | 39.20 |
|
| Prelude Therapeutics (PRLD) | 0.2 | $35M | 10M | 3.42 |
|
|
| DBV Technologies Sponsored Ads (DBVT) | 0.2 | $31M | 1.5M | 20.89 |
|
|
| Design Therapeutics (DSGN) | 0.2 | $28M | +15% | 2.6M | 10.64 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.2 | $27M | 671k | 39.72 |
|
|
| Cytomx Therapeutics (CTMX) | 0.1 | $23M | +17% | 5.0M | 4.70 |
|
| Jade Biosciences (JBIO) | 0.1 | $23M | 1.6M | 14.05 |
|
|
| Disc Medicine (IRON) | 0.1 | $22M | +3% | 350k | 63.94 |
|
| Immunocore Holdings Ads (IMCR) | 0.1 | $22M | -68% | 734k | 30.15 |
|
| Xenon Pharmaceuticals (XENE) | 0.1 | $22M | 370k | 58.15 |
|
|
| Celldex Therapeutics (CLDX) | 0.1 | $21M | 665k | 31.72 |
|
|
| Neurogene (NGNE) | 0.1 | $20M | 992k | 20.16 |
|
|
| Evommune Com Shs (EVMN) | 0.1 | $20M | NEW | 847k | 22.99 |
|
| Tectonic Therapeutic (TECX) | 0.1 | $19M | -32% | 608k | 30.91 |
|
| Contineum Therapeutics Cl A (CTNM) | 0.1 | $19M | 1.4M | 13.06 |
|
|
| argenx SE Sponsored Adr (ARGX) | 0.1 | $18M | 25k | 730.25 |
|
|
| Cerus Corporation (CERS) | 0.1 | $18M | 10M | 1.82 |
|
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.1 | $18M | 4.0M | 4.47 |
|
|
| Aktis Oncology | 0.1 | $18M | NEW | 996k | 17.89 |
|
| Generate Biomedicines Com Shs | 0.1 | $18M | NEW | 1.4M | 12.50 |
|
| Sionna Therapeutics (SION) | 0.1 | $16M | 400k | 40.09 |
|
|
| Dyne Therapeutics (DYN) | 0.1 | $15M | 813k | 18.13 |
|
|
| Xencor (XNCR) | 0.1 | $13M | 1.1M | 12.06 |
|
|
| COMPASS Pathways Sponsored Ads (CMPS) | 0.1 | $13M | NEW | 2.3M | 5.53 |
|
| Relay Therapeutics (RLAY) | 0.1 | $12M | 1.2M | 9.95 |
|
|
| Sera Prognostics Class A Com (SERA) | 0.1 | $11M | 5.5M | 2.03 |
|
|
| BioNTech SE Sponsored Ads (BNTX) | 0.1 | $11M | -67% | 120k | 88.88 |
|
| Pharvaris N V (PHVS) | 0.1 | $11M | 375k | 28.25 |
|
|
| Arcus Biosciences Incorporated (RCUS) | 0.1 | $9.0M | +53% | 416k | 21.60 |
|
| Maplight Therapeutics (MPLT) | 0.0 | $7.4M | 365k | 20.33 |
|
|
| Absci Corp (ABSI) | 0.0 | $6.4M | 2.1M | 3.00 |
|
|
| Wave Life Sciences SHS (WVE) | 0.0 | $6.0M | +139% | 823k | 7.25 |
|
| vTv Therapeutics Cl A (VTVT) | 0.0 | $5.9M | 148k | 39.66 |
|
|
| Eikon Therapeutics | 0.0 | $5.9M | NEW | 556k | 10.58 |
|
| Protara Therapeutics Com Stk (TARA) | 0.0 | $5.1M | 972k | 5.21 |
|
|
| Sagimet Biosciences Com Ser A (SGMT) | 0.0 | $5.0M | 953k | 5.22 |
|
|
| LB Pharmaceuticals Com Shs (LBRX) | 0.0 | $4.9M | 200k | 24.66 |
|
|
| Verastem (VSTM) | 0.0 | $3.1M | NEW | 585k | 5.30 |
|
| Tscan Therapeutics (TCRX) | 0.0 | $2.8M | 2.8M | 1.01 |
|
|
| Skye Bioscience (SKYE) | 0.0 | $968k | +8% | 1.6M | 0.61 |
|
| Sana Biotechnology (SANA) | 0.0 | $894k | 311k | 2.88 |
|
|
| Aligos Therapeutics (ALGS) | 0.0 | $617k | 83k | 7.43 |
|
|
| Tyra Biosciences (TYRA) | 0.0 | $406k | 11k | 38.30 |
|
|
| Surrozen W Exp 8/11/2026 (SRZNW) | 0.0 | $13k | 833k | 0.02 |
|
Past Filings by Baker Bros. Advisors
SEC 13F filings are viewable for Baker Bros. Advisors going back to 2010
- Baker Bros. Advisors 2026 Q1 filed May 15, 2026
- Baker Bros. Advisors 2025 Q4 filed Feb. 17, 2026
- Baker Bros. Advisors 2025 Q3 filed Nov. 14, 2025
- Baker Bros. Advisors 2025 Q2 filed Aug. 14, 2025
- Baker Bros. Advisors 2025 Q1 filed May 15, 2025
- Baker Bros. Advisors 2024 Q4 filed Feb. 14, 2025
- Baker Bros. Advisors 2024 Q3 filed Nov. 14, 2024
- Baker Bros. Advisors 2024 Q2 filed Aug. 14, 2024
- Baker Bros. Advisors 2024 Q1 filed May 15, 2024
- Baker Bros. Advisors 2023 Q4 filed Feb. 14, 2024
- Baker Bros. Advisors 2023 Q3 filed Nov. 14, 2023
- Baker Bros. Advisors 2023 Q2 filed Aug. 14, 2023
- Baker Bros. Advisors 2023 Q1 filed May 15, 2023
- Baker Bros. Advisors 2022 Q4 filed Feb. 14, 2023
- Baker Bros. Advisors 2022 Q3 filed Nov. 14, 2022
- Baker Bros. Advisors 2022 Q2 filed Aug. 15, 2022